Navigation Links
Lenalidomide, Granted Approval by FDA to Join Multiple Myeloma Drugs

Graham Burton, M.D., SVP, Regulatory Affairs and Pharmacovigilance said that FDA’s approval of REVLIMID (lenalidomide) offered a new oral drug option// to the group of people suffering from multiple myeloma.

Celgene Corporation (Nasdaq: CELG) announced that the U.S. Food and Drug Administration (FDA) has granted approval for its Supplemental New Drug Application (sNDA) for an additional indication for REVLIMID (lenalidomide), for use in combination with dexamethasone as a treatment for patients with multiple myeloma who have received at least one prior therapy. REVLIMID is also approved for use in the treatment of patients with transfusion-dependent anemia due to Low-or- Intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Multiple myeloma is the second most common blood cancer in the United States, affecting approximately 50,000 people. About 14,600 new cases of multiple myeloma are diagnosed each year and about 12,000 Americans are expected to die of multiple myeloma in 2006. In the REVLIMID (lenalidomide)/dexamethasone treatment group, 151 patients (45%) underwent at least one dose interruption with or without a dose reduction of REVLIMID (lenalidomide) compared to 21% in the placebo/dexamethasone treatment group. Most adverse events and Grade 3 or 4 adverse events were more frequent in patients who received the combination of REVLIMID (lenalidomide)/dexamethasone compared to placebo /dexamethasone.

‘The FDA approval of REVLIMID offers a new oral therapeutic option to this particular group of patients with multiple myeloma,’ said Graham Burton, M.D., SVP, Regulatory Affairs and Pharmacovigilance for Celgene. REVLIMID will be available in the following strengths: 5 mg, 10 mg, 15 mg, and 25 mg capsules.

Source: Eurekaler
'"/>




Page: 1

Related medicine news :

1. Bail Granted To The Doctor Despite Her Patients Death
2. Azerbaijan Granted 5 million dollars in Fight Against Bird Flu
3. Developer Of Vaccine For Cancer Granted A Prestigious Fellowship
4. American Senior Citizens Granted More Time
5. Numerous Defense Personnel Granted Early Retirement Due to Mental Illness
6. Approval for DNA test to detect cystic fibrosis
7. Vaccine For Cervical Cancer Awaits Approval
8. WHO Gives Its Approval For Bird Flu Test Kit
9. FDA Gives Its Approval For Inhaler
10. RotaTeq Gets US Approval
11. Better Communication With FDA Could Speed Up Approval Of New Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Lenalidomide Granted Approval FDA Join Multiple Myeloma Drugs

(Date:8/21/2014)... Raleigh, NC (PRWEB) August 21, 2014 ... proteins produced by Staph bacteria has been used to ... just posted an article on the new research. ... at the University of Western Australia treated mesothelioma ... that it killed the cancer cells while simultaneously stimulating ...
(Date:8/21/2014)... Obispo, CA (PRWEB) August 21, 2014 ... of Current Pedorthics, a bi-monthly publication of the Pedorthic Footcare ... of pedorthics. , Bunion Bootie is ... alternative solution for bunion sufferers and their pain. It is ... in nearly any shoe to eliminate the friction and rubbing ...
(Date:8/21/2014)... 21, 2014 According to a recent ... Ophthalmology, environmental factors may outweigh genetics in the development and ... of the world’s population is nearsighted, and this study provides ... “This is an important finding in the field of ophthalmology,” ... are we finding better ways to treat ophthalmological conditions ...
(Date:8/21/2014)... 21, 2014 Beverly Hills Medical Center of ... to offer patients TearLab, a new diagnostic option for measuring ... eye syndrome. , “ TearLab is a revolutionary new ... can accurately measure the amount of tears a patient produces ... Dr. Ghassan Zein, Medical Director at the Kuwait medical center. ...
(Date:8/21/2014)... Beverly Hills, CA (PRWEB) August 21, 2014 ... for your overall health. Juice cleanses offer clearer skin, more ... overall immune function. Pearl Recovery Retreat, a wellness center in ... programs right from the comfort of their recovery room. ... options to get them well again following surgery in our ...
Breaking Medicine News(10 mins):Health News:Study Finds Bacteria Compound Shrinks Mesothelioma Tumors, According to Surviving Mesothelioma 2Health News:Recently Featured in Current Pedorthics: Bunion Bootie, the Very Popular Bunion Treatment Splint 2Health News:Recently Featured in Current Pedorthics: Bunion Bootie, the Very Popular Bunion Treatment Splint 3Health News:Study Suggests Environmental Factors May Outweigh Genetics When It Comes to Myopia 2Health News:Beverly Hills Kuwait is the First Medical Center in Kuwait with Access to TearLab 2Health News:Los Angeles Surgery Recovery Center Now Offering Juice Cleanses 2Health News:Los Angeles Surgery Recovery Center Now Offering Juice Cleanses 3
... Corporation,("WorldHeart", Nasdaq: WHRT ), a pioneer in ... Alexander ("Alex") Martin as,President and CEO. Mr. Martin ... Mr. Martin joins WorldHeart from Edwards Lifesciences where ... Vice President since,2004. Previously, Alex was with Cordis ...
... Site Uses Search to Improve Point-of-Care Decisions ... leader in enterprise search, recently published a ... Platform(TM) helps health-care practitioners deliver faster and ... The case study details Vivisimo,s application for ...
... cancer risk almost 6-fold, researchers find , , FRIDAY, Feb. ... mutations that appear to predict a significant increased risk ... to early diagnosis and treatment, the researchers said. In ... and 1,590 deaths, according to the U.S. National Cancer ...
... University at Buffalo researcher John Violanti, Ph.D., a specialist ... a study on suicide risk among returning veterans. The ... number of soldiers taking their own lives., Violanti currently ... quickly persons associate feelings of self-harm, as a way ...
... Feb. 6 Masimo Corporation (Nasdaq: MASI ... and Low-Perfusion pulse oximetry, today announced that its management ... 21st Annual OC Growth Stock Conference at The Ritz-Carlton, ... 18, 2009, at 11:00 a.m. PT. A live audiocast ...
... Feb. 6 Optimal Reading Services Group, ... hospitals and radiology group practices, announced that its chief ... UBS Global Healthcare Services Conference on Monday, February 9, ... Hotel in New York City.Optimal leverages a deep pool ...
Cached Medicine News:Health News:WorldHeart Appoints New President and CEO 2Health News:WorldHeart Appoints New President and CEO 3Health News:New Vivisimo Case Study Details Medical Search 2Health News:Gene Test Could Predict Thyroid Cancer Risk 2Health News:Gene Test Could Predict Thyroid Cancer Risk 3Health News:Masimo to Present at the Roth Capital Partners 21st Annual OC Growth Stock Conference 2Health News:Optimal Readings to Present at 2009 UBS Global Healthcare Services Conference 2
(Date:8/20/2014)... Aug. 20, 2014  Decision Resources Group ... and ablation device market will expand through ... treat atrial fibrillation (AF). The increasing acceptance ... for AF will spur adoption of premium-priced ... as advanced loop diagnostic catheters, cryoablation catheters ...
(Date:8/20/2014)...  Amerigen Pharmaceuticals Ltd. announces that its Chinese ... Chinese FDA (CFDA) approval and has subsequently launched ... China domestic market.  Under ... with Sinochem Jiangsu Pharmaceutical Co., Ltd., Amerigen is ... and China CFDA certified oral solid dose facility ...
(Date:8/20/2014)... NEW YORK , Aug. 20, 2014 ... available in its catalogue: Global Feminine Hygiene ... This report analyzes the worldwide markets for Feminine ... Segments: Sanitary Pads/Towels, Tampons, Panty liners, and Others. The ... Canada , Japan , ...
Breaking Medicine Technology:Electrophysiology Mapping and Ablation Device Market in Japan to Reach $1.1 Billion by 2023 2Electrophysiology Mapping and Ablation Device Market in Japan to Reach $1.1 Billion by 2023 3Amerigen Pharmaceuticals Ltd. announces that its Chinese subsidiary, Suzhou Amerigen Pharmaceuticals Co. Ltd., has received Chinese FDA (CFDA) approval and has subsequently launched its generic Mecobalamin 0.5 mg Tablets into the China domestic mark 2Global Feminine Hygiene Products Industry 2Global Feminine Hygiene Products Industry 3Global Feminine Hygiene Products Industry 4Global Feminine Hygiene Products Industry 5Global Feminine Hygiene Products Industry 6Global Feminine Hygiene Products Industry 7Global Feminine Hygiene Products Industry 8Global Feminine Hygiene Products Industry 9Global Feminine Hygiene Products Industry 10Global Feminine Hygiene Products Industry 11Global Feminine Hygiene Products Industry 12Global Feminine Hygiene Products Industry 13Global Feminine Hygiene Products Industry 14Global Feminine Hygiene Products Industry 15Global Feminine Hygiene Products Industry 16Global Feminine Hygiene Products Industry 17Global Feminine Hygiene Products Industry 18Global Feminine Hygiene Products Industry 19Global Feminine Hygiene Products Industry 20Global Feminine Hygiene Products Industry 21Global Feminine Hygiene Products Industry 22Global Feminine Hygiene Products Industry 23Global Feminine Hygiene Products Industry 24Global Feminine Hygiene Products Industry 25Global Feminine Hygiene Products Industry 26
... (Nasdaq: VICL ),today is presenting expanded clinical ... Vaxfectin(R) adjuvant may be broadly,applicable in DNA- and ... P. Rolland, Pharm.D., Ph.D., Vical,s,Senior Vice President of ... 8, at the World Vaccine Congress (Lyon, France ...
... Texas, Oct. 7 The Texas Cardiac Arrhythmia,Institute ... selected as one of,only a few sites in ... for a new device to treat persistent atrial ... specializing in heart,rhythm disorders, is a partnership between ...
Cached Medicine Technology:Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 2Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 3Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 4Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 5Texas Cardiac Arrhythmia Institute at St. David's Medical Center Selected to Conduct Clinical Trial for Device to Treat Atrial Fibrillation 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: